Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lisdexamfetamine dimesylate
Drug ID BADD_D01299
Description Also known as _Vyvanse_, lisdexamfetamine (L-lysine-d-amphetamine) is a prodrug of the psychostimulant d-amphetamine [A40246]. It is paired with the essential amino acid _L-lysine_. Lisdexamfetamine dimesylate increases attention span and decreases restlessness in children and adults who are overactive/hyperactive, cannot concentrate for long periods, or are easily distracted or impulsive [A2230]. As a central nervous system stimulant, lisdexamfetamine is utilized as an adjunct therapy in the treatment of attention deficit hyperactivity disorder (ADHD). As a prodrug, lisdexamfetamine was specifically engineered as an abuse-resistant product [F2368]. The mechanism by which this occurs is through delayed release after ingestion (unlike some other psychostimulant drugs, which may be abused). After oral administration and absorption, enzyme hydrolysis after contact with red blood cells metabolize lisdexamfetamine into L- lysine, a naturally occurring essential amino acid and active _d-amphetamine_, which is responsible for the drug’s pharmacological effects. Gastrointestinal pH does not affect this conversion, and the addition of the L-lysine slows the amount of d-amphetamine available in the circulation and central nervous system [F2368].
Indications and Usage For the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in pediatric populations aged 6 to 12 years.
Marketing Status Prescription
ATC Code N06BA12
DrugBank ID DB01255
KEGG ID D04747
MeSH ID D000069478
PubChem ID 11597697
TTD Drug ID D00DEF
NDC Product Code 59116-3011; 59116-3012; 59417-102; 59417-107; 59417-116; 59417-120; 65392-0118; 59417-106; 59417-117; 59417-103; 59417-118; 59417-101; 59116-3013; 61960-0300; 59417-119; 51634-2058; 59116-3010; 59417-115; 59417-104; 17180-1100; 59417-105
Synonyms Lisdexamfetamine Dimesylate | Dimesylate, Lisdexamfetamine | Lis-dexamfetamine Dimesylate | Dimesylate, Lis-dexamfetamine | Lis dexamfetamine Dimesylate | Vyvanse | Elvanse | Lisdexamfetamine | NRP104 | NRP-104 | NRP 104
Chemical Information
Molecular Formula C17H33N3O7S2
CAS Registry Number 608137-33-3
SMILES CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N.CS(=O)(=O)O.CS(=O)(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain upper07.01.05.003--
Aggression19.05.01.001--Not Available
Agitation19.06.02.001; 17.02.05.012--
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Angioedema23.04.01.001; 10.01.05.009--Not Available
Anxiety19.06.02.002--
Asthenia08.01.01.001--Not Available
Blood pressure increased13.14.03.005--Not Available
Body temperature increased13.15.01.001--Not Available
Bruxism07.01.06.008; 19.11.03.001--Not Available
Cardiomyopathy02.04.01.001--Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Constipation07.02.02.001--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.002--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dry mouth07.06.01.002--
Dysgeusia07.14.03.001; 17.02.07.003--
Dyskinesia17.01.02.006--
Dyspepsia07.01.02.001--
Dysphoria19.04.02.004--Not Available
Dyspnoea22.02.01.004; 02.01.03.002--
Erythema multiforme23.03.01.003; 10.01.03.015--
Euphoric mood19.04.02.006--
Eye disorder06.08.03.001--Not Available
Fatigue08.01.01.002--
Feeling jittery08.01.09.016--Not Available
The 1th Page    1 2 3    Next   Last    Total 3 Pages